Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RIBOCICLIB vs RIFAMPIN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RIBOCICLIB vs RIFAMPIN: Safety Overview

Metric RIBOCICLIB RIFAMPIN
Total FAERS Reports 27,997 13,347
Deaths Reported 4,501 1,439
Death Rate 16.1% 10.8%
Hospitalizations 6,700 5,764
Average Patient Age 60.2 yrs 51.7 yrs
% Female Patients 99.0% 47.8%
FDA Approval Date Mar 13, 2017 Approved Prior to Jan 1, 1982
Manufacturer Novartis Pharmaceuticals Corporation Hikma Pharmaceuticals USA Inc.
Route ORAL INTRAVENOUS
Marketing Status Prescription Discontinued